EmailHospital Circular 10/2008
Date Issued: 25 March 2008
Distribution: Public Hospitals
Subject: Highly Specialised Drugs Program
Purpose: To advise hospitals of changes to the Highly Specialised Drugs Program, effective 1 April 2008
We have had recent advice from the Commonwealth Government of changes to the Highly Specialised Drugs Program, effective 1 April 2008.
ADDED ITEM
Sitaxentan Sodium
| 9622K | Tablet 100mg | 30 | Thelin | $2,743.80 | CS |
Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website.
AMENDED RESTRICTIONS
Bosentan Monohydrate
Epoprostenol Sodium
Iloprost Trometamol
Sildenafil Citrate
Treatment with the above drugs now recognises the listing of Sitaxentan Sodium
Tacrolimus
Now includes the prophylaxis and treatment of cardiac allograft rejection.
Full prescribing criteria for all items available at the Commonwealth/State Highly Specialised Drugs Program Guidelines website.
PRICE CHANGES
Lamivudine
| 6194B | Oral solution 10mg/ml | 240ml | 3TC | $86.48 | GK |
Stavudine
| 6250Y | Powder for oral solution 1mg/ml | 200ml | Zerit | $99.14 | BQ |
Changes notified by hospital circular will be updated in the Guidelines on the Commonwealth/State Highly Specialised Drugs Program Guidelines website and the claim form amended.
Geoff Lavender
Director, Programs
Metropolitan Health & Aged Care Services
